TCN2 and systemic lupus erythematosus: Of utmost importance, increases in unsaturated TCN2 (APO-TCN2) have been reported in patients with active autoimmune diseases including systemic lupus erythematous (SLE), autoimmune hemolytic anemia, and dermatomyositis, with levels often correlating with disease activity (146–148).